Gainers

• Apimeds Pharmaceuticals (AMEX:APUS) shares rose 23.4% to $6.07 during Friday's pre-market session. The market value of their outstanding shares is at $7.4 million.
• Firefly Neuroscience (NASDAQ:AIFF) shares moved upwards by 22.57% to $1.46. The company's market cap stands at $18.6 million.
• Stablecoin Development (AMEX:SDEV) stock increased by 17.82% to $1.52. The company's market cap stands at $34.9 million.
• Onconetix (NASDAQ:ONCO) shares moved upwards by 17.46% to $1.07. The company's market cap stands at $3.9 million.
• Actuate Therapeutics (NASDAQ:ACTU) stock rose 12.79% to $0.7. The market value of their outstanding shares is at $14.8 million.
• Greenland Mines (NASDAQ:GRML) shares moved upwards by 11.35% to $16.58. The market value of their outstanding shares is at $113.4 million.

Losers

• Burning Rock Biotech (NASDAQ:BNR) stock decreased by 22.2% to $14.01 during Friday's pre-market session. The company's market cap stands at $189.8 million.
• Pomdoctor (NASDAQ:POM) stock declined by 15.47% to $0.82. The market value of their outstanding shares is at $8.9 million.
• GlucoTrack (NASDAQ:GCTK) shares decreased by 12.41% to $2.26. The market value of their outstanding shares is at $2.0 million.
• Scinai Immunotherapeutics (NASDAQ:SCNI) stock declined by 11.83% to $1.64. The market value of their outstanding shares is at $1.2 million.
• Traws Pharma (NASDAQ:TRAW) shares decreased by 8.92% to $0.51. The company's market cap stands at $8.6 million.
• NexGel (NASDAQ:NXGL) stock declined by 8.4% to $0.24. The market value of their outstanding shares is at $2.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.